Skip to main
INCY

Incyte (INCY) Stock Forecast & Price Target

Incyte (INCY) Analyst Ratings

Based on 21 analyst ratings
Buy
Strong Buy 29%
Buy 19%
Hold 52%
Sell 0%
Strong Sell 0%

Bulls say

Incyte is well-positioned for growth in the biotech industry due to its diverse portfolio of small-molecule drugs, strong partnerships with major pharmaceutical companies, and successful launches of its leading drug Jakafi. With a promising pipeline of oncology and dermatology programs, the company has the potential to expand its market presence and drive future revenue growth. The recent positive CHMP opinion for Opzelura in atopic dermatitis and potential for a simpler subsequent presentation for subQ delivery of Jakafi through the ENHANZE technology also add to the company's positive outlook. With solid financials and a defined growth strategy, Incyte is a strong investment opportunity in the biotech sector.

Bears say

Incyte is facing numerous valuation and risk concerns as it operates in the highly competitive pharmaceutical industry. Despite having a strong partnership with Novartis and a diverse portfolio of marketed drugs, the lack of clarity on the timelines, bioavailability profile and economics of their ENHANZE formulation raise concerns for their long-term sustainability. Additionally, potential failures in ongoing clinical programs and risks related to efficacy, safety, and commercial costs are also major red flags for investors.

Incyte (INCY) has been analyzed by 21 analysts, with a consensus rating of Buy. 29% of analysts recommend a Strong Buy, 19% recommend Buy, 52% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Incyte and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Incyte (INCY) Forecast

Analysts have given Incyte (INCY) a Buy based on their latest research and market trends.

According to 21 analysts, Incyte (INCY) has a Buy consensus rating as of Aug 29, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $120.62, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $120.62, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Incyte (INCY)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.